$FCHS Cashflow Statement | Understand Stock

$FCHS

$0.01 +$0.00 (0.0%) Close

$FCHS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Net Loss
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation
Interest expense
Loss on disposition of assets
Amortization of debt discount
Amortization of deferred financing costs
Share-based compensation
Preferred dividends – accrued
Provision for bad debts
Loss on sale of equipment
Common stock issued in connection with loan extension
Impairment of investment
Loss on change in fair value of debt derivative
Common stock issued in settlement of litigation
Note payable issued in settlement of litigation
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other
Restricted funds
Employee loans
Accounts payable and accrued expenses
Settlement payable
Deposits
Deferred rent
Unearned income
Net cash provided by (used in) operating activities

Cash from variable interest entity
Other current assets
(Increase) decrease in leased assets
Deposit
Deferred tax asset
Accounts payable and accrued liabilities
(Increase) decrease in lease liabilities
(Decrease) Increase in lease liabilities
Net cash used in operating activities

Cash flows from investing activities:
Proceeds from sale of fixed assets
Payment of acquisition deposit
Purchase of property and equipment
Net decrease in deposits
Net cash provided by (used in) investing activities
Net (payments) proceeds from related party line of credit
Proceeds from advances
Proceeds from notes payable, related party
Proceeds from common stock subscription
Proceeds from lines of credit
Proceeds from issuance of notes payable, net of financing costs
Net cash provided by investing activities

Cash flows from financing activities:
Payments on notes payable
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Proceeds from issuance of convertible notes
Proceeds from sale of preferred stock
Net cash provided by financing activities

Net change in cash
Cash, beginning of period
Cash, end of period
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid during the period for taxes
Supplemental disclosure of cash flow information:
Note Payable addition from OID
Warrants issued for debt discount
Common shares issued for convertible notes - inducement
Line of Credit
Total common shares issued for convertible notes - inducement

Common stock issued in settlement of related party advances
Common stock issued in settlement of convertible note and related interest
Convertible Notes Payable
Notes Payable, Other Payables
Total common stock issued in settlement of convertible note and related interest
Common stock issued in settlement of related party line of credit
Common stock issued in connection with acquisition of patent
Common stock issued to acquire 10% interest in MedTech Diagnostics, LLC
Beneficial conversion feature on convertible note credited to additional paid-in-capital
Reclassification of derivative liability to additional paid-in-capital
Fair value of options issued to acquire management control of variable interest entity
Assets acquired from consolidation of variable interest entities

Comments